I saw some concern recently that the fda is considering not approving emergency authorization for kids when those vaccines are ready.
I hope that will turn out to be inaccurate, as I absolutely want DD to get the vaccine as soon as one is available to her.
There are different voices within the FDA, and they're trying to project forward based on several targets that move independently of each other.
One of the debates is whether to allow an EAU for younger children based on safety data alone, since the efficacy is so well established in adults and teenagers, and there really isn't any reason to suspect children won't get the same immunity benefit. Part of this is probably because some wish to have the results in time for next winter, so that kids won't need to endure another year of classroom disruption, but now that the pandemic has calmed down considerably in the US, Finland and Spain (where most of the trials are taking place), they may not be able to reach the efficacy targets in time.
So, the debate comes down to should we wait longer for more complete efficacy data in children (the safety data, on the other hand, will be more than adequate) and perhaps jeopardize another school year, or jump ahead and allow the vaccines for children, who are less likely to suffer severe consequences than adults anyway, with murkier efficacy numbers so that we can safely get them back to school full time? All of this also assumes the safety data holds up, which seems pretty likely to me. And now that we've relaxed and eliminated almost all mitigation measures, do we just want to sit back and see what damage the delta variant can inflict in unvaccinated children?
I don't claim to have the answers for these questions, and fortunately, I don't sit on an FDA advisory panel.